Sugi Predict

Sugi Predict / Compounds / SCHEMBL29530951

SCHEMBL29530951

SCHEMBL29530951

NC(=O)C[C@H](N)C(=O)N[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 5/20 0.55
▸ NAALAD2 Q9Y3Q0 3/20 0.55
▸ RIMKLA Q8IXN7 1/20 0.55
▸ GRM8 O00222 1/20 0.46
▸ GRM6 O15303 1/20 0.46
▸ GRIN2D O15399 1/20 0.46
▸ GRIN3B O60391 1/20 0.46
▸ GSR P00390 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ GRIK1 P39086 1/20 0.46
▸ GRM5 P41594 1/20 0.46
▸ GRIA1 P42261 1/20 0.46
▸ GRIA2 P42262 1/20 0.46
▸ GRIA3 P42263 1/20 0.46
▸ SLC1A3 P43003 1/20 0.46
▸ SLC1A2 P43004 1/20 0.46
▸ SLC1A1 P43005 1/20 0.46
▸ GRIA4 P48058 1/20 0.46
▸ GRIN1 Q05586 1/20 0.46
▸ GRIN2A Q12879 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30663332 1.00 FOLH1 (0.55) FOLH1NAALAD2RIMKLAGRM8GRM6
SCHEMBL29888969 0.95 FOLH1 (0.50) FOLH1NAALAD2RIMKLAGRM8GRM6
SCHEMBL29606838 0.94 FOLH1 (0.49) FOLH1NAALAD2RIMKLAGRM8GRM6
SCHEMBL31410836 0.94 FOLH1 (0.49) FOLH1NAALAD2RIMKLAGRM8GRM6
SCHEMBL16081765 0.94 NOD1 (0.52) FOLH1NAALAD2RIMKLANOD1ECE1
SCHEMBL5970326 0.92 KMT2A (0.50) FOLH1NAALAD2RIMKLADPP4DPP8
SCHEMBL5970329 0.92 KMT2A (0.50) FOLH1NAALAD2RIMKLADPP4DPP8
SCHEMBL29630347 0.91 FOLH1 (0.46) FOLH1NAALAD2RIMKLAECE1GNPAT
SCHEMBL1276949 0.90 FOLH1 (0.58) FOLH1NAALAD2RIMKLAGRM8GRM6
SCHEMBL10165828 0.90 FOLH1 (0.58) FOLH1NAALAD2RIMKLAGRM8GRM6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12377110-B2 Fospropofol methods and compositions EPALEX CORPORATION (US) 2025-08-05 — — US claimed
WO-2025002589-A1 TISSUE EXTRACELLULAR PEPTIDE PATTERNS DEDICATED FOR GENERATION OF ANTI-CANCER VACCINES AGAINST SALIVARY GLAND TUMOR, IDENTIFICATION AND ISOLATION OF SALIVARY GLAND TUMOR SPECIFIC T CELLS IN HUMANS Uniwersytet Gdański (PL) 2025-01-02 — — WO claimed
CN-116836223-A Prinsepia utilis royle active peptide composition and new application thereof 昆明理工大学 2023-10-03 — — CN claimed
US-20230084521-A1 PROPOFOL PRODRUG METHODS AND COMPOSITIONS EPALEX CORPORATION 2023-03-16 — — US claimed
US-20220105050-A1 PROPOFOL PRODRUG METHODS AND COMPOSITIONS EPALEX CORPORATION 2022-04-07 — — US claimed
EP-4707387-A2 ATTENUATED DENGUE VIRUSES Codagenix Inc. (US) 2026-03-11 — — EP disclosed
US-20250312361-A1 FOSPROPOFOL METHODS AND COMPOSITIONS EPALEX CORP (US) 2025-10-09 — — US disclosed
US-12377110-B2 Fospropofol methods and compositions EPALEX CORPORATION (US) 2025-08-05 — — US disclosed
US-12312390-B2 Rapid-acting insulin analogues of enhanced stability CASE WESTERN RESERVE UNIVERSITY (US) 2025-05-27 — — US disclosed
CN-120005928-A Dynamic regulation and control system, strain, construction method of strain and application of strain in microbial fuel cell 天津科技大学 2025-05-16 — — CN disclosed
WO-2025002589-A1 TISSUE EXTRACELLULAR PEPTIDE PATTERNS DEDICATED FOR GENERATION OF ANTI-CANCER VACCINES AGAINST SALIVARY GLAND TUMOR, IDENTIFICATION AND ISOLATION OF SALIVARY GLAND TUMOR SPECIFIC T CELLS IN HUMANS Uniwersytet Gdański (PL) 2025-01-02 — — WO disclosed
US-12178869-B2 Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer CODAGENIX INC. (US) 2024-12-31 — — US disclosed
US-20220347285-A1 ATTENUATED DENGUE VIRUSES CODAGENIX INC. (US) 2022-11-03 — — US disclosed
CN-115109816-A Method for preparing elastin peptide, elastin peptide prepared thereby and uses thereof 安徽盛美诺生物技术有限公司 2022-09-27 — — CN disclosed
US-20220298492-A1 ATTENUATED VIRUSES USEFUL FOR VACCINES THE RESEARCH FOUNDATION FOR THE STATE OF UNIV NEW YORK (US) 2022-09-22 — — US disclosed
US-20220265686-A1 FOSPROPOFOL METHODS AND COMPOSITIONS EPALEX CORPORATION 2022-08-25 — — US disclosed
WO-2022169520-A1 FOSPROPOFOL METHODS AND COMPOSITIONS EPALEX CORPORATION (US) 2022-08-11 — — WO disclosed
EP-3990014-A1 ATTENUATED DENGUE VIRUSES Codagenix Inc. (US) 2022-05-04 — — EP disclosed
US-20220112262-A1 RAPID-ACTING INSULIN ANALOGUES OF ENHANCED STABILITY CASE WESTERN RESERVE UNIVERSITY 2022-04-14 — — US disclosed
US-20220105050-A1 PROPOFOL PRODRUG METHODS AND COMPOSITIONS EPALEX CORPORATION 2022-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250312361-A1 FOSPROPOFOL METHODS AND COMPOSITIONS FOS, FOSB, PFAS FOLH1 387/4885NAALAD2 4066/4885RIMKLA 1929/4885
US-12377110-B2 Fospropofol methods and compositions FOS, FOSB, PFAS FOLH1 387/4885NAALAD2 4066/4885RIMKLA 1929/4885
US-20220265686-A1 FOSPROPOFOL METHODS AND COMPOSITIONS FOS, FOSB, PFAS FOLH1 387/4885NAALAD2 4066/4885RIMKLA 1929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.